Close Menu

NEW YORK — Saga Diagnostics said on Tuesday that it has signed agreements to perform liquid biopsy testing on cancer patients enrolled in clinical studies for French pharmaceutical firm Servier.

Saga said that it will use its digital PCR-based Sagasafe platform to detect and quantify circulating tumor DNA (ctDNA) in patients from up to three Servier clinical trials. The deal, which also covers preclinical studies, runs for approximately two years.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.